Neuroscience
Oral drug for MS significantly reduces disease activity and slows disability
The drug laquinimod reduced the number of relapses for people with multiple sclerosis (MS), in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the ...
Apr 11, 2011
0
0